

1 **Multi-organ impairment in low-risk individuals with long COVID**

2 Andrea Dennis PhD<sup>1</sup>, *Head of Biomarker Science, Perspectum*

3 [andrea.dennis@perspectum.com](mailto:andrea.dennis@perspectum.com)

4 Malgorzata Wamil PhD<sup>2,3</sup>, *Consultant Cardiologist* [gosia.wamil@googlemail.com](mailto:gosia.wamil@googlemail.com)

5 Sandeep Kapur MBBS<sup>4</sup>, *Associate Medical Director* [kapur.sandeep@mayo.co.uk](mailto:kapur.sandeep@mayo.co.uk)

6 Johann Alberts MBBCh<sup>5</sup>, *Medical Director* [jalberts@alliance.co.uk](mailto:jalberts@alliance.co.uk)

7 Andrew D. Badley MD<sup>6</sup>, *Professor of Medicine & Chair, Mayo Clinic COVID Research*

8 *Taskforce* [badley.andrew@mayo.edu](mailto:badley.andrew@mayo.edu)

9 Gustav Anton Decker MBBCh<sup>6</sup>, *President, Mayo Clinic International*

10 [decker.anton@mayo.edu](mailto:decker.anton@mayo.edu)

11 Stacey A Rizza<sup>6</sup>, *Professor of Medicine* [Rizza.stacey@mayo.edu](mailto:Rizza.stacey@mayo.edu)

12 Rajarshi Banerjee DPhil\*<sup>1,3</sup>, *Chief Executive and Honorary Consultant Physician*

13 [rajarshi.banerjee@perspectum.com](mailto:rajarshi.banerjee@perspectum.com)

14 Amitava Banerjee DPhil\*<sup>7,8,9</sup>, *Associate Professor of Clinical Data Science and Honorary*

15 *Consultant Cardiologist* [ami.banerjee@ucl.ac.uk](mailto:ami.banerjee@ucl.ac.uk)

16 On behalf of the COVERSCAN study investigators (listed at the end of manuscript)

17

18 <sup>1</sup>*Perspectum, 5520 John Smith Drive, Oxford, OX4 2LL, UK*

19 <sup>2</sup>*Great Western Hospitals NHS Foundation Trust*

20 <sup>3</sup>*Oxford University Hospitals NHS Foundation Trust*

21 <sup>4</sup>*Mayo Clinic Healthcare, 15 Portland Pl, Marylebone, London W1B 1PT*

22 <sup>5</sup>*Alliance Medical Limited, Icen Centre, Warwick Technology Park, Warwick, CV34 6DA*

23 <sup>6</sup>*Mayo Clinic | 200 First Street SW, Rochester, MN 55905*

24 <sup>7</sup>*Institute of Health Informatics, University College London, 222 Euston Road, London, UK*

25 <sup>8</sup>*University College London Hospitals NHS Trust, 235 Euston Road, London, UK*

26 <sup>9</sup>*Barts Health NHS Trust, The Royal London Hospital, Whitechapel Rd, London, UK*

27 \*joint senior author

28

29 - **Corresponding authors:** [ami.banerjee@ucl.ac.uk](mailto:ami.banerjee@ucl.ac.uk); [rajarshi.banerjee@perspectum.com](mailto:rajarshi.banerjee@perspectum.com)

30

31

32

33

34

35

36

37

38

39

40

## 41 **Multi-organ impairment in low-risk individuals with long COVID**

### 42 **Abstract**

43 **Background:** Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection  
44 has disproportionately affected older individuals and those with underlying medical  
45 conditions. Research has focused on short-term outcomes in hospital, and single organ  
46 involvement. Consequently, impact of long COVID (persistent symptoms three months post-  
47 infection) across multiple organs in low-risk individuals is yet to be assessed.

48 **Methods:** An ongoing prospective, longitudinal, two-centre, observational study was  
49 performed in individuals symptomatic after recovery from acute SARS-CoV-2 infection.  
50 Symptoms and organ function (heart, lungs, kidneys, liver, pancreas, spleen) were assessed  
51 by standardised questionnaires (EQ-5D-5L, Dyspnoea-12), blood investigations and  
52 quantitative magnetic resonance imaging, defining single and multi-organ impairment by  
53 consensus definitions.

54 **Findings:** Between April and September 2020, 201 individuals (mean age 44 (SD 11.0)  
55 years, 70% female, 87% white, 31% healthcare workers) completed assessments following  
56 SARS-CoV-2 infection (median 140, IQR 105-160 days after initial symptoms). The  
57 prevalence of pre-existing conditions (obesity: 20%, hypertension: 6%; diabetes: 2%; heart  
58 disease: 4%) was low, and only 18% of individuals had been hospitalised with COVID-19.  
59 Fatigue (98%), muscle aches (88%), breathlessness (87%), and headaches (83%) were the  
60 most frequently reported symptoms. Ongoing cardiorespiratory (92%) and gastrointestinal  
61 (73%) symptoms were common, and 42% of individuals had ten or more symptoms.  
62 There was evidence of mild organ impairment in heart (32%), lungs (33%), kidneys (12%),  
63 liver (10%), pancreas (17%), and spleen (6%). Single (66%) and multi-organ (25%)  
64 impairment was observed, and was significantly associated with risk of prior COVID-19  
65 hospitalisation ( $p<0.05$ ).

66 **Interpretation:** In a young, low-risk population with ongoing symptoms, almost 70% of  
67 individuals have impairment in one or more organs four months after initial symptoms of  
68 SARS-CoV-2 infection. There are implications not only for burden of long COVID but also  
69 public health approaches which have assumed low risk in young people with no  
70 comorbidities.

71 **Funding:** This work was supported by the UK's National Consortium of Intelligent Medical  
72 Imaging through the Industry Strategy Challenge Fund, Innovate UK Grant 104688, and also  
73 through the European Union's Horizon 2020 research and innovation programme under  
74 grant agreement No 719445.

75

76

## 77 **Introduction**

78 Early in the COVID-19 pandemic, research and clinical interest in SARS-CoV-2 (Severe  
79 acute respiratory syndrome-coronavirus 2)-induced organ damage was predominantly  
80 focused on the respiratory system(1). There have been indirect effects on other organ  
81 systems and disease processes, such as cardiovascular diseases and cancers, through  
82 changes in health systems or behaviours of patients and health professionals(2-4). In  
83 addition, beyond an acute systemic inflammatory response, evidence for direct COVID-19-  
84 related effects on multiple organs is accumulating, with potential long-term impacts for  
85 individuals as well as health systems(5-8). However, no study to-date has included detailed  
86 characterisation of all major organ systems following SARS-CoV-2 infection.

87

88 COVID-19 represents a convergence of an infectious disease, under-treated non-  
89 communicable diseases and social determinants of health, as a “syndemic”(9). Pre-existing  
90 non-communicable diseases and risk factors are important predictors of poor COVID-19  
91 outcomes, whether intensive care admissions or mortality(2). Research has focused on the  
92 acute phase of SARS-CoV-2 infection, in hospitalised patients, and on individuals that have  
93 died from COVID-19(10-12). It is clear that COVID-19 can have longer multiple symptoms  
94 and long-term effects(13), but “long-COVID” is yet to be fully defined(14-15), partly due to  
95 lack of understanding of medium- and long-term pathophysiology across organ systems.

96

97 Long COVID in low-risk individuals, who represent up to 80% of the population(2), has public  
98 health importance in terms of burden of disease and healthcare utilisation, and therefore has  
99 urgent policy relevance across countries. However, in the UK, government policies have  
100 emphasised excess risk of mortality in moderate- and high-risk conditions, including  
101 “shielding”(2) and commissioning of a risk calculator to identify those at highest risk of  
102 COVID-19 severity and mortality(16). As the pandemic progresses, there is growing concern  
103 regarding prolonged isolation strategies for people with vulnerable conditions and at highest  
104 risk of severe COVID-19 outcomes(17). These approaches have assumed low risk of SARS-  
105 CoV-2 infection in younger individuals without underlying conditions, based on their low  
106 excess mortality, but without knowledge of the chronic pulmonary and extrapulmonary  
107 effects of COVID-19.

108

109 In order to better understand the long-term impact of COVID-19 and ultimately inform  
110 preventive measures at health system level, we performed a pragmatic, prospective study in  
111 low-risk individuals with symptom assessment, multi-organ magnetic resonance imaging

112 (MRI) and blood investigations for inflammatory markers at three months post-COVID-19  
113 diagnosis.

## 114 **Methods**

### 115 *Patient population and study design*

116 In an ongoing, prospective study, 201 participants were enrolled at two UK sites  
117 (Perspectum, Oxford and Mayo Clinic Healthcare, London) between April 2020 and August  
118 2020 and completed baseline assessment by 14 September 2020 (**Figure 1**). Participants  
119 were eligible for enrolment if they tested positive by the oro/nasopharyngeal throat swab for  
120 SARS-CoV-2 by reverse-transcriptase-polymerase-chain reaction (n=62), a positive antibody  
121 test (n=63), or had typical symptoms and were determined to have COVID-19 by two  
122 independent clinicians (n=73). Exclusion criteria were symptoms of active respiratory viral  
123 infection (temperature >37.8°C or three or more episodes of coughing in 24 hours);  
124 discharged from hospital in the last 7 days; and contraindications to MRI, including implanted  
125 pacemakers, defibrillators, other metallic implanted devices; claustrophobia. The study  
126 protocol was approved by a UK ethics committee (20/SC/0185), registered  
127 (<https://clinicaltrials.gov/ct2/show/NCT04369807>) and all patients gave written informed  
128 consent.

129

### 130 **To assess the burden of multi-organ involvement after SARS-CoV2 infection**

131 Organ function was assessed by patient-reported validated questionnaires, fasting blood  
132 investigations (as listed below) and multi-organ MRI. MRI was the chosen imaging modality  
133 (as in UK Biobank) because it is: (1) safe, with no radiation exposure, no need for  
134 intravenous contrast, minimal contact with the radiographer; (2) quantitative, repeatable and  
135 robust, with >95% acquisition and image processing success rate; (3) informative through a  
136 repository of digital data which can be shared in the research community for independent  
137 analysis and research; (4) rapid and scalable, i.e. a 35-minute scan can phenotype the lung,  
138 heart, kidney, liver, pancreas and spleen. At time of MRI, we completed (i) questionnaires for  
139 quality of life (EQ-5D-5L(18)), addressing mobility, self-care, usual activity, pain and anxiety,  
140 and breathlessness (Dyspnoea-12(19)) and (ii) full blood count, serum biochemistry (sodium,  
141 chloride, bicarbonate, urea, creatinine, bilirubin, alkaline phosphatase, aspartate transferase,  
142 alanine transferase, lactate dehydrogenase, creatinine kinase, gamma-glutamyl  
143 transpeptidase, total protein, albumin, globulin, calcium, magnesium, phosphate, uric acid,  
144 fasting triglycerides, cholesterol (total, HDL, LDL), iron, iron-binding capacity (unsaturated  
145 and total) and inflammatory markers (erythrocyte sedimentation rate, ESR; high sensitivity-  
146 C-Reactive Protein, CRP) (TDL laboratories, London).

147

### 148 **Magnetic Resonance Image Analysis**

149 Multi-organ MRI data were collected at both study sites (Oxford: MAGNETOM Aera 1.5T,  
150 Mayo Healthcare London; MAGNETOM Vida 3T; both from Siemens Healthcare Erlangen,  
151 Germany). The COVERSCAN Multiparametric MRI assessment typically required 35mins per  
152 patient, including lungs, heart, liver, pancreas, kidneys and spleen by standardised  
153 methodology (**Supplementary methods**).

154

#### 155 **Definition of organ impairment**

156 MRI-derived measurements from the heart, lungs, kidney, liver, pancreas and spleen were  
157 compared with established reference ranges (**Table S1**) to determine impairment for each  
158 organ. An individual organ was classified as impaired if at least one of the metrics calculated  
159 for that organ was outside the reference range. Excessive organ fat was not considered as  
160 an indicator of impairment on the assumption that this was likely pre-existing and thus  
161 treated separately. Organ impairment was defined for each metric according to established  
162 cut-offs (Table S1) and was grouped by evidence of: borderline or low ejection fraction and  
163 evidence of myocarditis in the heart; reduced pulmonary dynamic measurements in the  
164 lungs; elevated cortical T1 in the kidneys; borderline or definite inflammation in the liver and  
165 pancreas; and splenomegaly from spleen length.

166

#### 167 **Statistical analysis**

168 All statistical analyses were performed using R software (version 3.6.1) with a p-value less  
169 than 0.05 considered statistically significant. Descriptive statistics were used to summarise  
170 baseline participant characteristics. Mean and standard deviation (SD) were used to  
171 describe normally distributed-continuous variables, median with interquartile range (IQR) for  
172 non-normally distributed, and frequency and percentage for categorical variables.

173

174 Mean difference in quantitative organ metrics between hospitalised versus not hospitalised  
175 were compared using the Wilcoxon test, and difference in the counts of the binary outcomes  
176 of those with evidence of organ abnormalities compared using Fisher's test. Multi-organ  
177 impairment was defined as impairment to  $\geq 2$  organs. Associations between multi-organ  
178 impairment and symptoms, comorbidities and pre-existing risk factors were assessed using  
179 Spearman's correlation. Based on the observed differences between hospitalised and non-  
180 hospitalised groups, multivariate logistic regression models were used to assess risk factors  
181 for COVID-19 hospitalisation.

182

183

184

185

186

187

188

## 189 **Results**

190 The mean age was 44.0 (SD: 11.0) years. 70% of individuals were female, 87% were white,  
191 31% were healthcare workers, 18% had been hospitalised with COVID-19. Assessment  
192 (symptoms, blood and MRI) was a median 140 (IQR 105-160) days after initial symptoms.  
193 Relevant past medical history included smoking (3%), asthma (18%), obesity (20%),  
194 hypertension (6%), diabetes (2%) and heart disease (4%). The hospitalised group were  
195 older ( $p=0.001$ ), had a higher proportion of non-white participants ( $p=0.038$ ), and were more  
196 likely to report 'inability to walk' ( $p=0.01$ ) than non-hospitalised individuals. There were no  
197 other significant differences between risk factors or symptoms reported between the groups.  
198 The most commonly reported on-going symptoms (regardless of hospitalisation status) were  
199 fatigue (98%), muscle ache (88%), shortness of breath (87%) and headache (83%) (**Table 1**,  
200 **Figure 2(a)**). Ongoing cardiorespiratory (92%) and gastrointestinal (73%) symptoms were  
201 common. 99% of individuals had four or more and 42% had ten or more symptoms. 52% of  
202 patients reported persistent moderate problems undertaking usual activities (level 3 or  
203 greater in the relevant EQ-5D-5L question). 20% reported Dyspnoea-12  $\geq 15$  (equivalent to  
204  $\sim 3$  on the MRC dyspnoea grade).

205

### 206 *Blood investigations*

207 Triglycerides ( $p=0.002$ ), cholesterol ( $p=0.021$ ), LDL-cholesterol ( $p=0.005$ ) and transferrin  
208 saturation ( $p=0.005$ ) were more likely to be abnormal in hospitalised versus non-hospitalised  
209 individuals. Mean corpuscular haemoglobin concentration (26%), alanine transferase (14%),  
210 lactate dehydrogenase (16%), triglycerides (12%) and cholesterol (42%) were all abnormally  
211 high in  $\geq 10\%$  of all individuals (without separation by hospitalisation status). ESR (13%),  
212 bicarbonate (13%), uric acid (16%) and high-sensitivity CRP (13%) were abnormally high in  
213 in  $\geq 10\%$  of individuals in the hospitalisation group. Bicarbonate (10%), phosphate (13%), uric  
214 acid (11%), and transferrin saturation (19%) were abnormally low in  $\geq 10\%$  of individuals  
215 (without separation by hospitalisation status) (**Table S2**).

216

### 217 *Single and multi- organ impairment*

218 Impairment was present in the heart in 32% (myocarditis in 11%; systolic dysfunction in  
219 23%), lungs in 33%, kidneys in 12%, liver in 10%, pancreas in 17%, and 6% had evidence of  
220 splenomegaly (**Table 2**, **Figure 2(b)**). 66% of individuals had impairment in one or more  
221 organ systems. There was evidence of multi-organ impairment in 25% of individuals, with  
222 varying degrees of overlap across multiple organs (**Figure 1 and 3**). Organ impairment was

223 more common in hospitalised versus non-hospitalised individuals. Measures of inflammation  
224 in the kidneys and pancreas, and ectopic fat in the pancreas and liver, were also higher in  
225 hospitalised individuals (all  $p < 0.05$ )(**Figure 2(b)**).

226

227 *Association between symptoms, blood investigations and organ impairment*

228 **Figure 4** shows the percentage of reported symptoms in those with organ impairment (per  
229 organ). Multi-organ involvement was associated with more serious symptoms (fatigue,  
230 breathlessness etc), but no clear pattern was observed linking symptoms to organ  
231 impairment. Regression analysis did not show any association between specific organ  
232 impairment and specific symptoms or blood investigations. Increasing age (OR: 1.06 [CI:  
233 1.02-1.10],  $p < 0.01$ ), increased liver volume (OR: 1.18 [CI: 1.06-1.30],  $p < 0.001$ ) and having  
234 multi-organ impairment (OR: 2.75 [CI:1.22-6.22],  $p < 0.05$ ), all significantly increased the  
235 likelihood of being hospitalized, adjusting for gender and BMI.

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263 **Discussion**

264 In the first study to-date evaluating medium-term impairment across multiple organs  
265 following SARS-CoV2 infection, we had three major findings. First, in young individuals,  
266 largely without risk factors, pre-existing disease or hospitalisation, there was significant  
267 symptom burden and evidence of heart, lung, liver and pancreas impairment four months  
268 post-COVID-19. Second, symptoms and blood investigations predicted neither organ  
269 impairment nor hospitalisation. Third, cardiac (myocarditis and systolic dysfunction) and lung  
270 impairment have similar prevalence in low-risk individuals with long COVID.

271

272 The short-term symptoms likely to predict COVID-19(20) persist four months post-infection,  
273 particularly fatigue, shortness of breath, myalgia, headache and arthralgia. In this young  
274 cohort with low prevalence of comorbidities, the extent of symptom burden and organ  
275 impairment is concerning. Models of population COVID-19 impact have been based on age,  
276 underlying conditions and mortality, excluding morbidity or potential for multi-organ  
277 impairment and chronic diseases(21, 22). Moreover, studies highlighting extrapulmonary  
278 COVID-19 manifestations emphasised acute phase of illness(20). Although we describe mild  
279 rather than severe organ impairment, the pandemic's scale and high infection rates in lower  
280 risk individuals (by age and underlying conditions), suggest a medium- and longer- term  
281 impact of SARS-CoV-2 infection which cannot be ignored in healthcare or policy spheres.

282

283 Although there may be an immunologic basis for variations in progression and severity of  
284 SARS-CoV-2 infection in different individuals(24), prediction models to-date have high rates  
285 of bias and poor performance(25). We found clustering of cardiorespiratory and  
286 gastrointestinal symptoms with evidence of impairment in heart, liver and pancreas  
287 respectively, but blood investigations were not associated with particular patterns of organ  
288 impairment as determined by COVERSCAN multi-organ assessment. Neither symptoms nor  
289 blood investigations were predictive of organ impairment. In acutely unwell patients, the  
290 focus has been on recognition of respiratory dysfunction and early provision of ventilatory  
291 support, but chronic multi-organ function has not been described systematically. Ongoing  
292 studies are considering chronic impact of COVID-19(26) but excluding non-hospitalised, low-  
293 risk individuals with and without organ impairment, which we will be investigating further in  
294 the longer term. As well as interest in specialist long COVID clinical services(27), there is a  
295 role for multi-organ assessment and ongoing evaluation, including low-risk, non-hospitalised  
296 individuals, perhaps even in the absence of symptoms.



297

298 Acute myocarditis and cardiogenic shock have been described(28), as well as high  
299 prevalence of myocarditis in hospitalised COVID-19 patients(29). In American athletes,  
300 although recent COVID-19 was associated with myocarditic changes, many non-infected  
301 patients also showed these changes(30). We now add that one third of low-risk individuals  
302 with long COVID syndrome have cardiac impairment in the form of mild systolic dysfunction  
303 or myocarditis three months following SARS-CoV-2 infection. Whilst causality cannot be  
304 attributed, cardiac function can be viewed as a risk factor for severe infection and an  
305 explanation of persistent symptoms in long COVID. As longitudinal data across organs  
306 become available, potential significance of our findings in the liver, kidney and pancreas  
307 needs to be explored.

### 308 *Implications for research*

309 Our findings at four months post-infection and future findings have three research  
310 implications. First, as countries face second pandemic waves, models of the pandemic's  
311 impact must include long COVID, whether quality of life, healthcare utilisation, productivity  
312 and economic effects. Second, there is urgent need for further multi-organ assessment,  
313 including blood and imaging analysis in the COVID-19 context, as well as linkage with  
314 primary and secondary care data, so that long COVID can be properly defined. Third, further  
315 longitudinal investigation of clustering of symptoms and organ impairment will inform health  
316 services research to plan multidisciplinary care pathways.

### 317 *Implications for clinical practice and public health*

318 There are three implications for COVID-19 management. First, as well as highlighting the  
319 potential for MRI across organ systems following SARS-CoV-2 infection, our findings signal  
320 the need for monitoring and follow-up in at least the medium- and longer-term, especially for  
321 extrapulmonary sequelae. Second, as the search for effective COVID-19 vaccines and  
322 treatments continues, potential and real long-term multi-organ consequences of SARS-CoV-  
323 2 infection in low-risk individuals reinforce the central importance of minimising infection  
324 through social distancing, wearing of masks, physical isolation and other population-level  
325 measures. Third, both in terms of managing baseline risk, and monitoring and treating  
326 complications across organ systems, long COVID requires management across specialities  
327 (e.g. cardiology, gastroenterology) and disciplines (e.g. communicable and non-  
328 communicable diseases).

### 329 *Strengths and limitations*

330 Our study is an ongoing, prospective, longitudinal cohort study with detailed blood and  
331 imaging characterisation of organ function, despite limited clinical examination with video  
332 consultations in the era of COVID-19. By recruiting ambulatory patients after infection with

333 broad inclusion criteria (e.g. SARS-CoV-2 testing by virus RNA, antibody or antigen), we  
334 focus on individuals at lower risk of severity and mortality from acute SARS-CoV-2 infection.  
335 Our cardiac MRI protocol excluded gadolinium contrast as concerns regarding COVID-19-  
336 related renal complications remain. We relied on native T1 mapping to detect and  
337 characterise myocardial inflammation, allowing non-invasive tissue characterisation which  
338 was previously evaluated as superior to gadolinium MRI for acute myocarditis(31).

339

340 We report baseline findings following SARS-CoV-2 infection. In our pragmatic study design,  
341 the diagnosis of COVID-19 was by multiple methods, partly limited by access to laboratory  
342 testing during the pandemic. Causality of the relationship between organ impairment and  
343 infection cannot be deduced, but may be addressed by longitudinal follow-up of individuals  
344 with organ impairment. Our study population was limited by ethnicity despite  
345 disproportionate impact of COVID-19 in non-white individuals. Pulse oximetry and spirometry  
346 were added later to the protocol and follow up; they were not included from the outset to limit  
347 interaction and exposure between trial team and patients. We did not include healthy  
348 controls or MRI assessment of brain or muscle function.

349

### 350 *Conclusions*

351 Long COVID has a physiological basis, with measurable patient-reported outcomes and  
352 organ impairment. Medium- and long-term evaluation and monitoring of multi-organ function  
353 beyond symptoms and blood investigations is likely to be required, even in lower risk  
354 individuals. Health system responses should emphasise suppression of population infection  
355 rates, as well as management of pre- and post-COVID-19 risk factors and chronic diseases.

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373 *COVERSCAN study investigators*

374 *Perspectum*: Mary Xu, Faezah Sanaei-Nezhad, Andrew Parks, Andrea Borghetto, Matthew

375 D Robson, Petrus Jacobs, John Michael Brady, Carla Cascone, Soubera Rymell, Jacky Law,

376 Virginia Woolgar, Velko Tonev, Claire Herlihy, Rob Suriano, Tom Waddell, Henrike Puchte,

377 Alessandra Borlotti, Arun Jandor, Freddie Greatrex, Robin Jones, Georgina Pitts, Ashleigh

378 West, Marion Maguire, Anu Chandra, Naomi Jayaratne, Dali Wu, Stella Kin, Mike Linsley,

379 Valentina Carapella, Isobel Gordon, George Ralli, John McGonigle, Darryl McClymont,

380 Boyan Ivanov, James Owler, Diogo Cunha, Tatiana Lim, Carlos Duncker, Madison Wagner,

381 Marc Goldfinger, Adriana Roca, Charlotte Erpicum, Matthew David Kelly, Rexford D

382 Newbould, Catherine J Kelly, Andrea Dennis, Sofia Mouchti, Arina Kazimianec, Helena

383 Thomaides-Briers, Rajarshi Banerjee

384 *Mayo Clinic*: Sandeep Kapur, Louise McLaughlin, Stacey A. Rizza

385 *University College London*: Amitava Banerjee

386 *Great Western Hospitals NHS Foundation Trust*: Malgorzata Wamil

387 *University of Oxford*: Yi-Chun Wang, Tom Waddell

388 **Contributorship statement:**

389 Study design: AD, SK, RB, JA, SR

390 Patient recruitment: SK, RB, COVERSCAN team

391 Data collection: MW, LM, COVERSCAN team

392 Data analysis: AD, COVERSCAN team, AB

393 Data interpretation: AB, AD, MW, RB

394 Initial manuscript drafting: AB, AD, RB

395 Critical review of early and final versions of manuscript: all authors

396 Specialist input: cardiology (MW, AB); general medicine (RB, ADB, GAD); infectious disease

397 (SAR, ADB); imaging (MR, RB); statistics (AD); epidemiology/public health (AB); primary

398 care (SK); healthcare management (JA).

399 **Funding acknowledgements**

400 AB is supported by research funding from NIHR, British Medical Association, Astra-Zeneca,

401 UK Research and Innovation, and the Innovative Medicines Initiative-2 (BigData@Heart

402 Consortium, under grant agreement No. 116074, supported by the European Union's

403 Horizon 2020 research and innovation programme and EFPIA; chaired by DE Grobbee and

404 SD Anker, partnering with 20 academic and industry partners and ESC). This work was

405 supported by the UK's National Consortium of Intelligent Medical Imaging through the  
406 Industry Strategy Challenge Fund, Innovate UK Grant 104688, and also through the  
407 European Union's Horizon 2020 research and innovation programme under grant agreement  
408 No 719445.

409

## 410 **Research in Context**

411

### 412 ***Evidence before this study***

413 We searched PubMed, medRxiv, bioRxiv, arXiv, and Wellcome Open Research for peer-  
414 reviewed articles, preprints, and research reports on long COVID syndrome and medium-  
415 and long-term impact of coronavirus disease 2019 (COVID-19), using the search terms  
416 "coronavirus", "COVID-19", and similar terms, "organ impairment", "organ function" and  
417 "morbidity", up to September 30, 2020. We found no prior studies of medium- or long-term  
418 multi-organ impairment due to COVID-19. Prior studies have considered acute phase of  
419 illness and hospitalised patients, focusing on "high-risk" individuals based on age and  
420 underlying conditions. Without longer term data including lower risk individuals, full  
421 population impact of the pandemic cannot be assessed and health system responses cannot  
422 be planned.

423

### 424 ***Added value of this study***

425 In 201 individuals with low risk for COVID-19 severity and mortality (mean age 44 years,  
426 20% obesity, 6% hypertension, 2% diabetes and 4% heart disease, 18% hospitalised), we  
427 assessed symptoms, blood investigations and multi-organ magnetic resonance imaging  
428 across organ systems, four months following SARS-CoV-2 infection. 99% and 42% had  $\geq 4$   
429 and  $\geq 10$  symptoms respectively. Mild organ impairment was present in at least one organ in  
430 66% and in 2 or more organs in 25% of individuals. Multi-organ impairment was associated  
431 with hospitalisation.

432

### 433 **Implications of all the available evidence**

434 These analyses support strategies to suppress and minimise the infection rate in the  
435 population; medium- and long-term follow-up after SARS-CoV-2 infection with detailed  
436 evaluation across organ systems; and management of underlying conditions and risk factors  
437 before and after infection. For the first time, we provide multi-organ assessment in young,  
438 low-risk individuals with long COVID to inform healthcare and policy responses.

439

440

441

442  
443  
444  
445  
446  
447  
448

## References

- 449 1. World Health Organization. Clinical management of severe acute respiratory infection  
450 (SARI) when COVID-19 disease is suspected. Interim guidance 13 March 2020.  
451 [https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-](https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf)  
452 [cov.pdf](https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf)
- 453 2. Banerjee A, Pasea L, Harris S, Gonzalez-Izquierdo A, Torralbo A, Shallcross L,  
454 Noursadeghi M, Pillay D, Sebire N, Holmes C, Pagel C, Wong WK, Langenberg C,  
455 Williams B, Denaxas S, Hemingway H. Estimating excess 1-year mortality from  
456 COVID-19 according to underlying conditions and age in England: a rapid analysis  
457 using NHS health records in 3.8 million adults. *Lancet* May 30;395(10238):1715-1725
- 458 3. Banerjee A, Chen S, Pasea L, Lai A, Katsoulis M, Denaxas S, Nafilyan V, Williams B,  
459 Wong WK, Bakhai A, Khunti K, Pillay D, Noursadeghi M, Wu H, Pareek N, Bromage  
460 D, Mcdonagh T, Byrne J, Teo JT, Shah A, Humberstone B, Tang LV, Shah ASV,  
461 Rubboli A, Guo Y, Hu Y, Sudlow CLM, Lip GYH, Hemingway H. Excess deaths in  
462 people with cardiovascular diseases during the COVID-19 pandemic. *Medrxiv*.  
463 Preprint. 2020. Online 11/6/2020.  
464 <https://www.medrxiv.org/content/10.1101/2020.06.10.20127175v1>
- 465 4. Lai AG, Pasea L, Banerjee A, Denaxas S, Katsoulis M, Chang WH, Williams B, Pillay  
466 D, Noursadeghi M, Swanton C, Linch D, Hughes D, Forster MD, Johnson P, Turnbull  
467 C, DATA-CAN, Cooper M, Jones M, Pritchard-Jones K, Sullivan R, Lawler M, Hall G,  
468 Davie C, Hemingway H. Estimating excess mortality in people with cancer and  
469 multimorbidity in the COVID-19 emergency. *BMJ Open*. 2020. In press.
- 470 5. Pavon AG, Meier D, Samim D, Rotzinger DC, Fournier S, Marquis P, Monney P,  
471 Muller O, Schwitter J. First Documentation of Persistent SARS-Cov-2 Infection  
472 Presenting With Late Acute Severe Myocarditis. *Can J Cardiol*. 2020  
473 Aug;36(8):1326.e5-1326.e7.
- 474 6. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: The current evidence.  
475 *United European Gastroenterol J*. 2020 Jun;8(5):509-519.
- 476 7. Farouk SS, Fiaccadori E, Cravedi P, Campbell KN. COVID-19 and the kidney: what  
477 we think we know so far and what we don't. *J Nephrol*. 2020 Jul 20:1-6.

- 478 8. Somasundaram NP, Ranathunga I, Ratnasamy V, Wijewickrama PSA, Dissanayake  
479 HA, Yogendranathan N, Gamage KKK, de Silva NL, Sumanatilleke M, Katulanda P,  
480 Grossman AB. The Impact of SARS-Cov-2 Virus Infection on the Endocrine System.  
481 J Endocr Soc. 2020 Jul 2;4(8):bvaa082.
- 482 9. Horton R. Offline: COVID-19 is not a pandemic. Lancet 2020. 396; 874.
- 483 10. Shovlin CL, Vizcaychipi MP. Implications for COVID-19 triage from the ICNARC  
484 report of 2204 COVID-19 cases managed in UK adult intensive care units. Emerg  
485 Med J. 2020 Jun;37(6):332-333.
- 486 11. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA,  
487 Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S,  
488 Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning  
489 J, Openshaw PJ, Baillie JK, Semple MG; ISARIC4C investigators. Features of  
490 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical  
491 Characterisation Protocol: prospective observational cohort study. BMJ. 2020 May  
492 22;369:m1985. doi: 10.1136/bmj.m1985.
- 493 12. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ,  
494 Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson  
495 L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H,  
496 Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L,  
497 Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY.  
498 Nature. 2020 Jul 8. doi: 10.1038/s41586-020-2521-4.
- 499 13. World Health Organization. What we know about Long-term effects of COVID-19.9  
500 September 2020. [https://www.who.int/docs/default-source/coronaviruse/risk-comms-](https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update-36-long-term-symptoms.pdf?sfvrsn=5d3789a6_2)  
501 [updates/update-36-long-term-symptoms.pdf?sfvrsn=5d3789a6\\_2](https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update-36-long-term-symptoms.pdf?sfvrsn=5d3789a6_2)
- 502 14. Nabavi N. Long covid: How to define it and how to manage it. BMJ. 2020 Sep  
503 7;370:m3489.
- 504 15. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute  
505 covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026.
- 506 16. National Institute for Health Research. New risk prediction model could help improve  
507 guidance for people shielding from COVID-19. 23 June 2020.  
508 [https://www.nihr.ac.uk/news/new-risk-prediction-model-could-help-improve-guidance-](https://www.nihr.ac.uk/news/new-risk-prediction-model-could-help-improve-guidance-for-people-shielding-from-covid-19/25096)  
509 [for-people-shielding-from-covid-19/25096](https://www.nihr.ac.uk/news/new-risk-prediction-model-could-help-improve-guidance-for-people-shielding-from-covid-19/25096)
- 510 17. Wise J. Covid-19: Experts divide into two camps of action—shielding versus blanket  
511 policies. BMJ 2020;370:m3702. <https://www.bmj.com/content/370/bmj.m3702>
- 512 18. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P,  
513 Busschbach J. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L

- 514 across eight patient groups: a multi-country study. *Qual Life Res* 2013  
515 Sep;22(7):1717-1727
- 516 19. Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using  
517 descriptors: development and initial testing of the Dyspnoea-12. *Thorax*. 2010  
518 Jan;65(1):21-6. doi: 10.1136/thx.2009.118521. Epub 2009 Dec 8.
- 519 20. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, Ganesh S,  
520 Varsavsky T, Cardoso MJ, El-Sayed Moustafa JS, Visconti A, Hysi P, Bowyer RCE,  
521 Mangino M, Falchi M, Wolf J, Ourselein S, Chan AT, Steves CJ, Spector TD. Real-  
522 time tracking of self-reported symptoms to predict potential COVID-19. *Nat Med*.  
523 2020 Jul;26(7):1037-1040.
- 524 21. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B,  
525 Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer  
526 MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM,  
527 Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP,  
528 Landry DW. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020  
529 Jul;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3.
- 530 22. Palmer K, Monaco A, Kivipelto M, Onder G, Maggi S, Michel JP, Prieto R, Sykara G,  
531 Donde S. The potential long-term impact of the COVID-19 outbreak on patients with  
532 non-communicable diseases in Europe: consequences for healthy ageing. *Aging Clin  
533 Exp Res*. 2020 Jul;32(7):1189-1194.
- 534 23. Wyper GMA, Assunção R, Cuschieri S, Devleeschauwer B, Fletcher E, Haagsma JA,  
535 Hilderink HBM, Idavain J, Lesnik T, Von der Lippe E, Majdan M, Milicevic MS, Pallari  
536 E, Peñalvo JL, Pires SM, Plaß D, Santos JV, Stockton DL, Thomsen ST, Grant I.  
537 Population vulnerability to COVID-19 in Europe: a burden of disease analysis. *Arch  
538 Public Health*. 2020 May 29;78:47.
- 539 24. Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, Kuri-  
540 Cervantes L, Pampena MB, D'Andrea K, Manne S, Chen Z, Huang YJ, Reilly JP,  
541 Weisman AR, Ittner CAG, Kuthuru O, Dougherty J, Nzingha K, Han N, Kim J,  
542 Pattekar A, Goodwin EC, Anderson EM, Weirick ME, Gouma S, Arevalo CP, Bolton  
543 MJ, Chen F, Lacey SF, Ramage H, Cherry S, Hensley SE, Apostolidis SA, Huang  
544 AC, Vella LA; UPenn COVID Processing Unit, Betts MR, Meyer NJ, Wherry EJ. Deep  
545 immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic  
546 implications. *Science*. 2020 Sep 4;369(6508):eabc8511.
- 547 25. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ,  
548 Damen JAA, Debray TPA, De Vos M, Dhiman P, Haller MC, Harhay MO, Henckaerts  
549 L, Kreuzberger N, Lohman A, Luijken K, Ma J, Andaur CL, Reitsma JB, Sergeant JC,  
550 Shi C, Skoetz N, Smits LJM, Snell KIE, Sperrin M, Spijker R, Steyerberg EW, Takada

- 551 T, van Kuijk SMJ, van Royen FS, Wallisch C, Hoofst L, Moons KGM, van Smeden M.  
552 Prediction models for diagnosis and prognosis of covid-19 infection: systematic  
553 review and critical appraisal. *BMJ*. 2020 Apr 7;369:m1328. doi: 10.1136/bmj.m1328.
- 554 26. PHOSP-COVID: Post-HOSPitalisation COVID-19 study. <https://www.phosp.org/>  
555 27. NHS to offer 'long covid' sufferers help at specialist centres. 7 October 2020  
556 <https://www.england.nhs.uk/2020/10/nhs-to-offer-long-covid-help/>
- 557 28. Chau VQ, Giustino G, Mahmood K, Oliveros E, Neibart E, Oloomi M, Moss N, Mitter  
558 SS, Contreras JP, Croft L, Serrao G, Parikh AG, Lala A, Trivieri MG, LaRocca G,  
559 Anyanwu A, Pinney SP, Mancini DM. Cardiogenic Shock and Hyperinflammatory  
560 Syndrome in Young Males with COVID-19. *Circ Heart Fail*. 2020 Aug 26. doi:  
561 10.1161/CIRCHEARTFAILURE.120.007485. Online ahead of print.
- 562 29. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of Cardiovascular Magnetic  
563 Resonance Imaging in Patients Recently Recovered From Coronavirus Disease  
564 2019 (COVID-19). *JAMA Cardiol*. Published online July 27, 2020.  
565 doi:10.1001/jamacardio.2020.3557.
- 566 30. Rajpal S, Tong MS, Borchers J, et al. Cardiovascular Magnetic Resonance Findings  
567 in Competitive Athletes Recovering From COVID-19 Infection. *JAMA Cardiol*.  
568 Published online September 11, 2020. doi:10.1001/jamacardio.2020.4916.
- 569 31. Ferreira VM, Piechnik SK, Dall'Armellina E, Karamitsos TD, Francis JM, Ntusi N, et  
570 al. T1 mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-  
571 weighted and late gadolinium enhanced imaging. *JACC Cardiovasc Imaging*.  
572 2013;6(10):1048-58)
- 573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587



588

589

590

591

592

593

594

595

596 **Figures and Tables**

597

598 Table 1: Baseline demographics and symptoms in 201 low-risk individuals with long-COVID.

599 Table 2: Evidence of organ impairment in 201 low-risk individuals with long-COVID.

600

601 Figure 1: Natural history of long COVID, the COVERSCAN study in low-risk individuals  
602 (n=201) and policy recommendations.

603 Figure 2: Proportion of low-risk individuals with long-COVID by hospitalisation (n=201) for (a)  
604 symptoms; and (b) evidence of organ impairment.

605 Figure 3: Multi-organ impairment in low-risk individuals with long COVID by gender and  
606 hospitalisation (n=201).

607

608 Figure 4: Clustering of reported symptoms and organ impairment for individuals with long-  
609 COVID (n=201).

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624  
625  
626  
627  
628  
629

Table 1: Baseline demographics and symptoms in 201 low-risk individuals with long-COVID.\*

|                                                       | All<br>(n=201)<br>N (%)         | Not hospitalised<br>(n=164)<br>N(%) | Hospitalised<br>(n=37)<br>N(%) | p     |
|-------------------------------------------------------|---------------------------------|-------------------------------------|--------------------------------|-------|
| <b>Patient characteristics</b>                        |                                 |                                     |                                |       |
| Age (yrs, mean; sd)                                   | 44(11.0)                        | 43(10.9)                            | 50(10.0)                       | 0.001 |
| Female (No, %)                                        | 140(69.7)                       | 117(71.3)                           | 23(62.2)                       | 0.268 |
| BMI (kg.m <sup>-2</sup> , median; IQR)                | 25.7(22.7,28.1)                 | 25.3(22.6,27.7)                     | 27.2(23.1,31.0)                | 0.162 |
| <b>Ethnicity</b>                                      |                                 |                                     |                                |       |
| White                                                 | 174(86.6)                       | 146(89.0)                           | 28 (75.7)                      | 0.008 |
| Mixed                                                 | 3(1.5)                          | 3(1.8)                              | 0 (0)                          |       |
| South Asian                                           | 8(4.0)                          | 5(3.0)                              | 3 (8.1)                        |       |
| Black                                                 | 5(2.5)                          | 3(1.8)                              | 2 (5.4)                        |       |
| <b>Comorbidities and risks</b>                        |                                 |                                     |                                |       |
| <b>Smoking</b>                                        |                                 |                                     |                                |       |
| Never                                                 | 132 (65.7)                      | 108 (65.9)                          | 24 (64.9)                      | 0.75  |
| Current                                               | 6 (3.0)                         | 6 (3.7)                             | 0 (0.0)                        | 0.945 |
| Ex                                                    | 63 (31.3)                       | 50 (30.5)                           | 13 (35.1)                      | 0.48  |
| Health care worker                                    | 62 (30.8)                       | 49 (29.9)                           | 13 (35.1)                      | 0.357 |
| Asthma                                                | 36 (17.9)                       | 33(20.1)                            | 3 (8.1)                        | 0.099 |
| <b>BMI</b>                                            |                                 |                                     |                                |       |
| ≥25 kg/m <sup>2</sup>                                 | 112 (56.3)                      | 87 (53.7)                           | 25 (67.6)                      | 0.144 |
| ≥30 kg/m <sup>2</sup>                                 | 40 (20.1)                       | 28 (17.3)                           | 12 (32.4)                      | 0.103 |
| Hypertension                                          | 12 (6.0)                        | 10 (6.1)                            | 2 (5.4)                        | 0.541 |
| Diabetes                                              | 4 (2.0)                         | 4 (2.4)                             | 0 (0.0)                        | 0.551 |
| Previous heart disease                                | 8 (4.0)                         | 7 (4.3)                             | 1 (2.7)                        | 0.56  |
| <b>Symptoms</b>                                       |                                 |                                     |                                |       |
| Fatigue                                               | 197 (98.0)                      | 160 (97.6)                          | 37 (100.0)                     | 0.591 |
| Muscle ache                                           | 176 (87.6)                      | 145 (88.4)                          | 31 (83.8)                      | 0.408 |
| Shortness of breath                                   | 175 (87.1)                      | 140 (85.4)                          | 35 (94.6)                      | 0.617 |
| Headache                                              | 166 (82.6)                      | 139 (84.8)                          | 27 (73.0)                      | 0.097 |
| Joint pain                                            | 157 (78.1)                      | 128 (78.0)                          | 29 (78.4)                      | 0.92  |
| Fever                                                 | 151 (75.1)                      | 127 (77.4)                          | 24 (64.9)                      | 0.14  |
| Chest pain                                            | 147 (73.1)                      | 116 (70.7)                          | 31 (83.8)                      | 0.15  |
| Cough                                                 | 148 (73.6)                      | 119 (72.6)                          | 29 (78.4)                      | 0.54  |
| Sore throat                                           | 143 (71.1)                      | 120 (73.2)                          | 23 (62.2)                      | 0.228 |
| Diarrhoea                                             | 119 (59.2)                      | 92 (56.1)                           | 27 (73.0)                      | 0.066 |
| Abnormal pain                                         | 108 (53.7)                      | 91 (55.5)                           | 17 (45.9)                      | 0.062 |
| Wheezing                                              | 97 (48.3)                       | 74 (45.1)                           | 23 (62.2)                      | 0.087 |
| Inability to walk                                     | 81 (40.3)                       | 59 (36.0)                           | 22 (59.5)                      | 0.01  |
| Runny nose                                            | 68 (33.8)                       | 55 (33.5)                           | 13 (35.1)                      | 0.85  |
| <b>Time interval</b>                                  |                                 |                                     |                                |       |
| Initial symptoms-to-assessment (days: median, [IQR])  | (n=1 missing)<br>140 (105, 160) | (n=1 missing)<br>140 (106, 162)     | 138 (97, 150)                  | 0.092 |
| COVID-19 positive-to-assessment (days: median, [IQR]) | (n=3 missing)<br>70 (42, 112)   | (n=3 missing)<br>67 (39, 109)       | 105 (59, 126)                  | 0.105 |

\* Continuous data presented as means (SD) for normally distributed data and median (IQR) for non-normally distributed data and categorical as count (%). Comparisons between patients man

679 aged at home vs hospitalised were conducted using Wilcoxon Rank sum test for continuous data and  
 680 Fisher exact test for categorical data.

681  
 682  
 683  
 684  
 685


Table 2: Evidence of organ impairment in 201 low-risk individuals with long-COVID.

| Measurement                                                  | All (n=201) N(%)              | Not hospitalised (n=164) N(%) | Hospitalised (n=37) N(%)    | p     |
|--------------------------------------------------------------|-------------------------------|-------------------------------|-----------------------------|-------|
| <b>HEART</b>                                                 |                               |                               |                             |       |
| <b>Left ventricular ejection fraction (%)</b>                |                               |                               |                             |       |
| • Normal (>55%)                                              | 155 (77.1)                    | 129 (78.7)                    | 26 (70.3)                   | 0.079 |
| • Borderline impairment (50-55%)                             | 38 (18.9)                     | 31 (18.9)                     | 7 (18.9)                    |       |
| • Definite impairment (<50%)                                 | 8 (4.0)                       | 4 (2.4)                       | 4 (10.8)                    |       |
| <b>Left ventricular end diastolic volume (ml)</b>            |                               |                               |                             |       |
| • >214ml in M; >178ml in W                                   | 27 (13.4)                     | 18 (11.0)                     | 9 (24.3)                    | 0.057 |
| <b>Evidence of myocarditis</b>                               |                               |                               |                             |       |
| • ≥ 3 segments with high T1 (≥1264ms at 3T; ≥1015ms at 1.5T) | 22 (10.9)                     | 18 (11.0)                     | 4 (10.8)                    | 1     |
| <b>LUNGS</b>                                                 |                               |                               |                             |       |
| <b>Deep Breathing Fractional area change</b>                 |                               |                               |                             |       |
| • < 39%                                                      | (n= 11 missing)<br>63 (33.2)  | (n= 8 missing)<br>47 (30.1)   | (n= 3 missing)<br>16 (47.1) | 0.071 |
| <b>KIDNEYS</b>                                               |                               |                               |                             |       |
| <b>Kidney cortex T1</b>                                      |                               |                               |                             |       |
| • Normal (<1610 ms at 3T; <1191ms at 1.5T)                   | (n= 12 missing)<br>175 (88.4) | (n= 8 missing)<br>146 (90.7)  | (n= 4 missing)<br>29 (78.4) | 0.046 |
| • Definite impairment (≥1610ms at 3T; ≥1191ms at 1.5T)       | 23 (11.6)                     | 15 (9.3)                      | 8 (21.6)                    |       |
| <b>PANCREAS</b>                                              |                               |                               |                             |       |
| <b>Pancreatic inflammation (T1 in ms)</b>                    |                               |                               |                             |       |
| • Normal (<800ms)                                            | 157 (83.1)                    | 136 (87.2)                    | 21 (63.6)                   | 0.003 |
| • Borderline (800-865ms)                                     | 20 (10.6)                     | 11 (7.1)                      | 9 (27.3)                    |       |
| • Significant (>865ms)                                       | 12 (6.3)                      | 9 (5.8)                       | 3 (9.1)                     |       |
| <b>Pancreatic fat</b>                                        |                               |                               |                             |       |
| • Normal (<5%)                                               | (n= 6 missing)<br>126 (64.6)  | (n= 4 missing)<br>111 (69.4)  | (n= 2 missing)<br>15 (42.9) | 0.005 |
| • Borderline (5-10%)                                         | 44 (22.6)                     | 33 (20.6)                     | 11 (31.4)                   |       |
| • Significant(>10%)                                          | 25 (12.8)                     | 16 (10.0)                     | 9 (25.7)                    |       |
| <b>LIVER</b>                                                 |                               |                               |                             |       |
| <b>Liver Inflammation (cT1 in ms)</b>                        |                               |                               |                             |       |
| • Normal (<800ms)                                            | (n= 1 missing)<br>181 (90.5)  | (n= 1 missing)<br>150 (92.0)  | 31 (83.8)                   | 0.040 |
| • Borderline (800-825ms)                                     | 5 (2.5)                       | 5 (3.1)                       | 0 (0.0)                     |       |
| • Significant (>825ms)                                       | 14 (7.0)                      | 8 (4.9)                       | 6 (16.2)                    |       |
| <b>Liver fat</b>                                             |                               |                               |                             |       |
| • Normal (<5%)                                               | 162 (80.6)                    | 138 (84.1)                    | 24 (64.9)                   | 0.025 |
| • Borderline (5-10%)                                         | 18 (9.0)                      | 12 (7.3)                      | 6 (16.2)                    |       |
| • Definite (>10%)                                            | 21 (10.4)                     | 14 (8.5)                      | 7 (18.9)                    |       |
| <b>SPLEEN</b>                                                |                               |                               |                             |       |
| <b>Splenic length (mm)</b>                                   |                               |                               |                             |       |
| • Normal (Table S1)                                          | (n= 10 missing)<br>179(9.4)   | (n= 10 missing)<br>144(9.5)   | 35 (9.5)                    | 1     |
| • Borderline (Table S1)                                      | 12 (6.3)                      | 10 (6.5)                      | 2 (5.4)                     |       |

686  
 687  
 688  
 689

\* Data are presented as count (%). Comparisons between patients managed at home vs hospitalised were conducted using Fisher exact test.

690 Figure 1: Natural history of long COVID, the COVERSCAN study in low-risk individuals (n=201) and policy recommendations.




691  
692


693

694 Figure 2: Proportion of low-risk individuals with long-COVID by hospitalisation (n=201) for (a)  
695 symptoms; and (b) evidence of organ impairment.

696  
697 (a)




698  
699 (b)



700  
701  
702  
703

704 Figure 3 Multi-organ impairment in low-risk individuals with long COVID by gender and  
705 hospitalisation (n=201).



706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722


723

724

725

726

727 Figure 4: Clustering of reported symptoms and organ impairment for individuals with long-  
728 COVID (n=201).



729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747